Articles

Hess and a U.K. nuclear plant show what $50 billion gets in the energy market

For nearly the same price, nuclear will generate far more power — and a lot more headaches.

Drinking can hit your wallet as hard as your health

Alcohol can quietly undermine financial control, decision-making and long-term security.

Could BP move its listing to the U.S.? Why a new chair at the oil giant is stirring speculation.

Could the company once called British Petroleum make America its new home?

Lockheed Martin’s stock rocked by big profit miss, as problems with classified programs continue

Lockheed Martin’s stock led the S&P 500’s early decliners after a $1.6 billion charge led to a big profit miss.

Here are the stocks that could get a boost from Trump’s ‘AI Action Plan’

In tandem with a presidential speech on Wednesday, the Trump administration is set to roll out its “AI Action Plan,” and new executive orders on AI are expected.

Coca-Cola confirms Coke with cane sugar is coming, and its stock is falling

Coca-Cola says innovations will include real cane sugar in Coke, as President Donald Trump said, but stock falls as quarterly revenue came up a bit shy.

Yeti’s stock has been hot, and this ‘viral’ tote could be why

The Camino Carryall Tote is making waves on TikTok and is sold out in many colors. One analyst says that’s a sign Yeti is succeeding with its brand expansion.

General Motors absorbs $1.1 billion in tariff costs as profit tops estimates

Auto giant’s stock falls in premarket trading after it reveals $1.1 billion in tariff costs in the second quarter, despite mitigation efforts.

Home-buying incentives to increase in coming month, D.R. Horton says

D.R. Horton’s stock surges after profit and new home orders beat expectations, but sales incentives are likely to increase to boost demand.

This one money move guarantees you inflation-proof income in retirement

Upon retiring, cash out your 401(k) and buy a bond “ladder” of Treasury inflation-protected securities.

The stock market has been running low on investors who want to sell. That might be starting to shift.

Andrew Thrasher, founder of Thrasher Analytics, said the stock market has been low on sellers who may be starting to return.

Sarepta Therapeutics’ stock slips further as company bows to FDA pressure to halt shipments

Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy.
1 354 355 356 357 358 2,548